MedTrace Logo

TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes

NCT01829464 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2016-06-01

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the effect of TAK-875 (fasiglifam) in combination with sitagliptin on glycemic control in adults with type 2 diabetes.

Conditions

Interventions

DRUG

Placebo

TAK-875 placebo-matching tablets

DRUG

TAK-875

TAK-875 tablets

DRUG

TAK-875

TAK-875 tablets

Sponsors & Collaborators

Principal Investigators

  • Medical Director, MD · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2014-02-28
Completion
2014-03-31

Countries

  • United States
  • Argentina
  • Peru

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01829464 on ClinicalTrials.gov